Published in Obesity and Diabetes Week, October 30th, 2006
According to recent research from Japan, "We investigated the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) and their relation with clinical and metabolic parameters in nonobese type 2 diabetic patients. The plasma levels of TAFI and PAI-1 were evaluated in 47 nonobese type 2 diabetic patients and 31...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.